Arcutis Begins Phase 3 Trial of Zoryve Cream 0.3% for Moderate to Severe Atopic Dermatitis

Bitget2026/11/05 13:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arcutis Biotherapeutics enrolled the first participant in its Phase 3 INTEGUMENT-3 trial of Zoryve cream for moderate to severe atopic dermatitis.
The study will evaluate once-daily roflumilast cream 0.3% in patients ages 6 and older; results have not yet been presented.
The trial aims to expand Zoryve’s use beyond mild to moderate atopic dermatitis by assessing efficacy, safety and tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050800PRIMZONEFULLFEED9870684) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arcutis Begins Phase 3 Trial of Zoryve Cream 0.3% for Moderate to Severe Atopic Dermatitis

You may also like

Crypto prices